NCT05345002 2026-02-20
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
Clinical Trials
10 trialsNCT06358677 2026-02-13
FACE
University of Utah
Phase 2 Recruiting
NCT01409161 2025-12-17
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06439888 2025-12-01
LySATRA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT06731140 2025-11-17
Resilire
Fudan University
Phase 2 Recruiting
NCT06528769 2025-09-30
Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT06536413 2025-04-08
ATRA
The Methodist Hospital Research Institute
Phase 1/2 Recruiting
NCT06158412 2025-02-19
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT05832320 2024-05-10
Optimum Induction Therapy of Low-risk APL
Peking University People's Hospital
Phase NA Recruiting
NCT04793919 2024-04-15
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Associazione Italiana Ematologia Oncologia Pediatrica
Phase 2 Recruiting